Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2009

01-09-2009 | Preclinical Trial

BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer

Authors: Weiqiu Chen, Kaifeng Pan, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Youyong Lu, Weicheng You, Yuntao Xie

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Login to get access

Abstract

The data related to BRCA1 germline mutation in Chinese women with familial breast cancer is increasing. However, little is known the frequency of BRCA1 mutations in Chinese women with familial or early-onset breast cancer from Northern China, and few studies are available to investigate the clinicopathological characteristics of BRCA1 tumors in Chinese women. In this study, we detected germline mutations in BRCA1 in a cohort of 139 breast cancer patients who either have a family history of breast cancer (n = 68) or whose tumors are diagnosed at or before the age of 35 (n = 71) from Northern China. A total of 6 deleterious BRCA1 mutations were identified in this cohort, 4 of which (5587-1 del8, 3887 del AG, IVS21 + 1delG, and 2129 ins TG) are novel and one mutation (3478del5) detected in this study was only reported in Chinese population. The frequency of BRCA1 mutations in women with familial or early-onset breast cancer was 5.9% (4/68) or 2.8% (2/71) in this cohort, respectively; but the mutations were detected in 4 of 16(25.0%) familial breast cancer patients whose tumors were diagnosed before the age of 40. Moreover, BRCA1 mutation tumors tended to be high histological grade, and to be negative for ER, PgR, and Her-2 compared with tumors without BRCA1 mutations. Our study suggests that Chinese women with a family history of breast cancer whose tumors are diagnosed before age of 40 would be a suitable candidate for BRCA1 testing; and BRCA1 tumors in Chinese women exhibit an aggressive phenotype.
Literature
2.
go back to reference Parkin DM, Whelan SL, Ferlay J (2002) Cancer incidence in five continents, vol VIII. IARC Scientific Publications No. 155, Lyon, France Parkin DM, Whelan SL, Ferlay J (2002) Cancer incidence in five continents, vol VIII. IARC Scientific Publications No. 155, Lyon, France
3.
go back to reference McPherson K, Steel CM, Dixon JM (2000) Breast cancer––epidemiology, risk factors, and genetics. BMJ 309:1003 McPherson K, Steel CM, Dixon JM (2000) Breast cancer––epidemiology, risk factors, and genetics. BMJ 309:1003
6.
go back to reference Li WF, Hu Z, Rao NY, Song CG, Zhang B, Cao MZ et al (2007) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat. doi:10.1007/s10549-007-9708-3 Li WF, Hu Z, Rao NY, Song CG, Zhang B, Cao MZ et al (2007) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat. doi:10.​1007/​s10549-007-9708-3
8.
go back to reference Hu Z, Wu J, Liu CH, Lu JS, Luo JM, Han QX et al (2003) The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives. Hum Mutat 22:104. doi:10.1002/humu.9156 PubMedCrossRef Hu Z, Wu J, Liu CH, Lu JS, Luo JM, Han QX et al (2003) The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives. Hum Mutat 22:104. doi:10.​1002/​humu.​9156 PubMedCrossRef
10.
go back to reference Khoo US, Ngan HY, Cheung AN, Chan KY, Lu J, Chan VW et al (2000) Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations. Hum Mutat 16:88–89. doi:10.1002/1098-1004(200007)16:1≤88::AID-HUMU16≥3.0.CO;2-GPubMedCrossRef Khoo US, Ngan HY, Cheung AN, Chan KY, Lu J, Chan VW et al (2000) Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations. Hum Mutat 16:88–89. doi:10.1002/1098-1004(200007)16:1≤88::AID-HUMU16≥3.0.CO;2-GPubMedCrossRef
12.
go back to reference Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F et al (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294:1925–1933. doi:10.1001/jama.294.15.1925 PubMedCrossRef Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F et al (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294:1925–1933. doi:10.​1001/​jama.​294.​15.​1925 PubMedCrossRef
13.
go back to reference Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505–1510. doi:10.1016/S0140-6736(96)10109-4 Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505–1510. doi:10.​1016/​S0140-6736(96)10109-4
14.
go back to reference Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310–2318. doi:10.1200/JCO.2002.09.023 PubMedCrossRef Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310–2318. doi:10.​1200/​JCO.​2002.​09.​023 PubMedCrossRef
15.
go back to reference Xu Y, Yao L, Li H, Ouyang T, Li J, Wang T et al (2006) Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status. Breast Cancer Res Treat 97:49–55. doi:10.1007/s10549-005-9086-7 PubMedCrossRef Xu Y, Yao L, Li H, Ouyang T, Li J, Wang T et al (2006) Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status. Breast Cancer Res Treat 97:49–55. doi:10.​1007/​s10549-005-9086-7 PubMedCrossRef
17.
go back to reference Agrawal S, Eng C (2006) Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Hum Mol Genet 15:777–787. doi:10.1093/hmg/ddi492 PubMedCrossRef Agrawal S, Eng C (2006) Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Hum Mol Genet 15:777–787. doi:10.​1093/​hmg/​ddi492 PubMedCrossRef
18.
go back to reference Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689. doi:10.1086/301749 PubMedCrossRef Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689. doi:10.​1086/​301749 PubMedCrossRef
19.
go back to reference Li SS, Tseng HM, Yang TP, Liu CH, Teng SJ, Huang HW et al (1999) Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan. Hum Genet 104:201–204. doi:10.1007/s004390050936 PubMedCrossRef Li SS, Tseng HM, Yang TP, Liu CH, Teng SJ, Huang HW et al (1999) Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan. Hum Genet 104:201–204. doi:10.​1007/​s004390050936 PubMedCrossRef
20.
go back to reference Sng JH, Chang J, Feroze F, Rahman N, Tan W, Lim S, Lehnert M, van PS, Wong J (2000) The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Br J Cancer 82:538–542. doi:10.1054/bjoc.1999.0960 PubMedCrossRef Sng JH, Chang J, Feroze F, Rahman N, Tan W, Lim S, Lehnert M, van PS, Wong J (2000) The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. Br J Cancer 82:538–542. doi:10.​1054/​bjoc.​1999.​0960 PubMedCrossRef
Metadata
Title
BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer
Authors
Weiqiu Chen
Kaifeng Pan
Tao Ouyang
Jinfeng Li
Tianfeng Wang
Zhaoqing Fan
Tie Fan
Benyao Lin
Youyong Lu
Weicheng You
Yuntao Xie
Publication date
01-09-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0066-6

Other articles of this Issue 1/2009

Breast Cancer Research and Treatment 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine